Published online before print March 21, 2002, doi: 10.1161/01.RES.0000016164.02525.B4
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2002 American Heart Association, Inc.
Molecular Medicine |
CD36 Mediates the Cardiovascular Action of Growth Hormone-Releasing Peptides in the Heart
From the Faculty of Pharmacy and Department of Pharmacology (V.B., N.M., P.P., D.L., A.D., A.P, H.O.), Université de Montréal, Montreal, Canada; the Division of Hematology and Medical Oncology, Department of Medicine (M.F., R.L.S.), Weill Medical College, Cornell University, New York, NY; Biovitrum AB (T.S.), Stockholm, Sweden; and the Department of Pharmacology (E.E.), Université de Sherbrooke, Canada.
Correspondence to Dr Huy Ong, Faculty of Pharmacy, Université de Montréal, C.P. 6128, Succursale Centre-ville, Montreal, Quebec, H3C 3J7 Canada. E-mail huy.ong{at}umontreal.ca
Growth hormone-releasing peptides (GHRPs) are known as potent growth hormone secretagogues whose actions are mediated by the ghrelin receptor, a G protein-coupled receptor cloned from pituitary libraries. Hexarelin, a hexapeptide of the GHRP family, has reported cardiovascular activity. To identify the molecular target mediating this activity, rat cardiac membranes were labeled with a radioactive photoactivatable derivative of hexarelin and purified using lectin affinity chromatography and preparative gel electrophoresis. A binding protein of Mr 84 000 was identified. The N-terminal sequence determination of the deglycosylated protein was identical to rat CD36, a multifunctional glycoprotein, which was expressed in cardiomyocytes and microvascular endothelial cells. Activation of CD36 in perfused hearts by hexarelin was shown to elicit an increase in coronary perfusion pressure in a dose-dependent manner. This effect was lacking in hearts from CD36-null mice and hearts from spontaneous hypertensive rats genetically deficient in CD36. The coronary vasoconstrictive response correlated with expression of CD36 as assessed by immunoblotting and covalent binding with hexarelin. These data suggest that CD36 may mediate the coronary vasospasm seen in hypercholesterolemia and atherosclerosis.
Key Words: acute coronary syndromes • growth hormone-releasing peptides • CD36 scavenger receptor
This article has been cited by other articles:
 |
|
 |
|
  N. S. Kar, M. Z. Ashraf, M. Valiyaveettil, and E. A. Podrez Mapping and Characterization of the Binding Site for Specific Oxidized Phospholipids and Oxidized Low Density Lipoprotein of Scavenger Receptor CD36 J. Biol. Chem., March 28, 2008; 283(13): 8765 - 8771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P.Y. Koonen, M. Febbraio, S. Bonnet, J. Nagendran, M. E. Young, E. D. Michelakis, and J. R.B. Dyck CD36 Expression Contributes to Age-Induced Cardiomyopathy in Mice Circulation, November 6, 2007; 116(19): 2139 - 2147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Xu, J. Pang, H. Yin, M. Li, W. Hao, C. Chen, and J.-M. Cao Hexarelin suppresses cardiac fibroblast proliferation and collagen synthesis in rat Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2952 - H2958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rodrigue-Way, A. Demers, H. Ong, and A. Tremblay A Growth Hormone-Releasing Peptide Promotes Mitochondrial Biogenesis and a Fat Burning-Like Phenotype through Scavenger Receptor CD36 in White Adipocytes Endocrinology, March 1, 2007; 148(3): 1009 - 1018. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Iantorno, H. Chen, J.-a Kim, M. Tesauro, D. Lauro, C. Cardillo, and M. J. Quon Ghrelin has novel vascular actions that mimic PI 3-kinase-dependent actions of insulin to stimulate production of NO from endothelial cells Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E756 - E764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Avallone, A. Demers, A. Rodrigue-Way, K. Bujold, D. Harb, S. Anghel, W. Wahli, S. Marleau, H. Ong, and A. Tremblay A Growth Hormone-Releasing Peptide that Binds Scavenger Receptor CD36 and Ghrelin Receptor Up-Regulates Sterol Transporters and Cholesterol Efflux in Macrophages through a Peroxisome Proliferator-Activated Receptor {gamma}-Dependent Pathway Mol. Endocrinol., December 1, 2006; 20(12): 3165 - 3178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M D. Robertson, A. S Bickerton, A L. Dennis, H. Vidal, and K. N Frayn Insulin-sensitizing effects of dietary resistant starch and effects on skeletal muscle and adipose tissue metabolism Am. J. Clinical Nutrition, September 1, 2005; 82(3): 559 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Holst, E. Brandt, A. Bach, A. Heding, and T. W. Schwartz Nonpeptide and Peptide Growth Hormone Secretagogues Act Both as Ghrelin Receptor Agonist and as Positive or Negative Allosteric Modulators of Ghrelin Signaling Mol. Endocrinol., September 1, 2005; 19(9): 2400 - 2411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Caminos, O. Gualillo, F. Lago, M. Otero, M. Blanco, R. Gallego, T. Garcia-Caballero, M. B. Goldring, F. F. Casanueva, J. J. Gomez-Reino, et al. The Endogenous Growth Hormone Secretagogue (Ghrelin) Is Synthesized and Secreted by Chondrocytes Endocrinology, March 1, 2005; 146(3): 1285 - 1292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Rindi, A. Torsello, V. Locatelli, and E. Solcia Ghrelin Expression and Actions: A Novel Peptide for an Old Cell Type of the Diffuse Endocrine System Experimental Biology and Medicine, November 1, 2004; 229(10): 1007 - 1016. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. van der Lely, M. Tschop, M. L. Heiman, and E. Ghigo Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin Endocr. Rev., June 1, 2004; 25(3): 426 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Wierup, S. Yang, R. J. McEvilly, H. Mulder, and F. Sundler Ghrelin Is Expressed in a Novel Endocrine Cell Type in Developing Rat Islets and Inhibits Insulin Secretion from INS-1 (832/13) Cells J. Histochem. Cytochem., March 1, 2004; 52(3): 301 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Thompson, D. A. S. Gill, R. Davies, N. Loveridge, P. A. Houston, I. C. A. F. Robinson, and T. Wells Ghrelin and Des-Octanoyl Ghrelin Promote Adipogenesis Directly in Vivo by a Mechanism Independent of the Type 1a Growth Hormone Secretagogue Receptor Endocrinology, January 1, 2004; 145(1): 234 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A Lucchesi Growth hormone-releasing peptides and the heart: secretagogues or cardioprotectors? Cardiovasc Res, January 1, 2004; 61(1): 7 - 8. [Full Text] [PDF]
|
|
|
|
|
|
X.-B. Xu, J.-M. Cao, J.-J. Pang, R.-K. Xu, C. Ni, W.-L. Zhu, K. Asotra, M.-C. Chen, and C. Chen The Positive Inotropic and Calcium-Mobilizing Effects of Growth Hormone-Releasing Peptides on Rat Heart Endocrinology, November 1, 2003; 144(11): 5050 - 5057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Torsello, E. Bresciani, G. Rossoni, R. Avallone, G. Tulipano, D. Cocchi, I. Bulgarelli, R. Deghenghi, F. Berti, and V. Locatelli Ghrelin Plays a Minor Role in the Physiological Control of Cardiac Function in the Rat Endocrinology, May 1, 2003; 144(5): 1787 - 1792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Baldanzi, N. Filigheddu, S. Cutrupi, F. Catapano, S. Bonissoni, A. Fubini, D. Malan, G. Baj, R. Granata, F. Broglio, et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT J. Cell Biol., December 23, 2002; 159(6): 1029 - 1037. [Abstract] [Full Text] [PDF]
|
|